Indexed protocols
Trial corpus
22 recruiting or active protocols with structured inclusion and exclusion criteria. Query-time merge pulls additional recruiting studies from ClinicalTrials.gov for the extracted condition.
- NCT06758401
Sigvotatug Vedotin plus Pembrolizumab in Advanced NSCLC
Non-Small Cell Lung Cancer · NSCLC
Pfizer
Phase 3
- NCT07222566
PF-08634404 plus Pembrolizumab in Advanced NSCLC (Symbiotic-Lung-01)
Advanced Non-Small Cell Lung Cancer · NSCLC
Pfizer
Phase 3
- NCT07765888
Tilrekimig in Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer
Phase 3
- NCT05431088
Osivelotor in Adult and Adolescent Sickle Cell Disease
Sickle Cell Disease
Pfizer
Phase 2/3
- NCT07595549
Berobenatide (PF-08653944) in People With Overweight or Obesity
Obesity · Overweight
Pfizer
Phase 3
- NCT07146906
Zigakibart in IgA Nephropathy
IgA Nephropathy · IgAN
Novartis Pharmaceuticals
Phase 2
- NCT06470048
Ianalumab in Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
- NCT06824103
Ruxolitinib in Corticosteroid-Refractory Chronic GVHD
Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
- NCT04741997
Neoadjuvant Encorafenib + Binimetinib in BRAF V600 Melanoma
Melanoma Stage III · Melanoma Stage IV · BRAF V600 Mutation
H. Lee Moffitt Cancer Center
Early Phase 1
- NCT06924320
MET233 with MET097 in Obesity or Overweight with T2D
Obesity · Type 2 Diabetes
Pfizer
Phase 1/2
- NCT05113251
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer
HER2-Positive Breast Cancer · Metastatic Breast Cancer
Daiichi Sankyo / AstraZeneca
Phase 3
- NCT04862741
Teclistamab in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Janssen / IQVIA-supported sites
Phase 2
- NCT04519125
Sacubitril/Valsartan in HFrEF with Residual Congestion
Heart Failure with Reduced Ejection Fraction
Novartis Pharmaceuticals
Phase 4
- NCT05271604
Pembrolizumab plus Lenvatinib in MSI-H / dMMR Colorectal Cancer
Colorectal Cancer · MSI-H · dMMR
Merck / IQVIA sites
Phase 3
- NCT04975178
Olaparib Maintenance in BRCA-Mutated High-Grade Ovarian Cancer
Ovarian Cancer · BRCA1/2
AstraZeneca
Phase 3
- NCT05644132
Risankizumab in Moderately to Severely Active Crohn's Disease
Crohn's Disease
AbbVie / IQVIA
Phase 3
- NCT04111510
Resmetirom in Nonalcoholic Steatohepatitis with Fibrosis
NASH · MASLD
Madrigal
Phase 3
- NCT03819127
Osimertinib in EGFR-Mutant Stage IV NSCLC
EGFR-Mutant NSCLC
AstraZeneca
Phase 3
- NCT04460872
Deucravacitinib in Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Bristol Myers Squibb
Phase 3
- NCT05501886
Acoramidis in Transthyretin Amyloid Cardiomyopathy
ATTR-CM · Transthyretin Amyloid Cardiomyopathy
BridgeBio
Phase 3
- NCT03334617
Venetoclax plus Obinutuzumab in Previously Untreated CLL
Chronic Lymphocytic Leukemia
Genentech / Roche
Phase 3
- NCT06288100
Flatiron-network EHR Matching Cohort: Solid Tumor Basket
Solid Tumors · NSCLC · Breast Cancer
Flatiron Health Research Network
Observational